Home/Filings/4/0000950170-25-026652
4//SEC Filing

Cabell Christopher 4

Accession 0000950170-25-026652

CIK 0001750149other

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 4:10 PM ET

Size

5.4 KB

Accession

0000950170-25-026652

Insider Transaction Report

Form 4
Period: 2025-02-21
Cabell Christopher
President & Head of R&D
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-02-21+1,100,7051,100,705 total
    Exercise: $2.23Exp: 2035-02-21Common Stock (1,100,705 underlying)
Footnotes (1)
  • [F1]The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.

Documents

1 file

Issuer

Inhibikase Therapeutics, Inc.

CIK 0001750149

Entity typeother

Related Parties

1
  • filerCIK 0001814928

Filing Metadata

Form type
4
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 4:10 PM ET
Size
5.4 KB